We are live on
!
Find out more
FCM
Farallon Capital Management Portfolio holdings
AUM
$21.7B
1-Year Est. Return
79.24%
This Fund
S&P 500
This Quarter
Est. Return
+33.18%
1 Year Est. Return
+79.24%
3 Year Est. Return
+204.51%
5 Year Est. Return
+270.91%
10 Year Est. Return
+1,884.18%
AUM
$21.7B
AUM Growth
+$2.61B
(+14%)
Cap. Flow
-$3.46B
Cap. Flow
% of AUM
-15.95%
Top 10 Holdings %
Top 10 Hldgs %
62.14%
Holding
194
New
19
Increased
30
Reduced
23
Closed
105
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Boston Scientific
BSX
|
+$166M |
| 2 |
Roivant Sciences
ROIV
|
+$137M |
| 3 |
Immunovant
IMVT
|
+$130M |
| 4 |
BridgeBio Pharma
BBIO
|
+$96.5M |
| 5 |
Baidu
BIDU
|
+$94.1M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Microsoft
MSFT
|
+$498M |
| 2 |
Amazon
AMZN
|
+$398M |
| 3 |
SCHW
Charles Schwab
SCHW
|
+$372M |
| 4 |
Aon
AON
|
+$365M |
| 5 |
Alphabet (Google) Class C
GOOG
|
+$286M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 54.84% |
| 2 | Miscellaneous | 21.83% |
| 3 | Communication Services | 8.41% |
| 4 | Technology | 5.7% |
| 5 | Financials | 3.99% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
176
Travere Therapeutics
TVTX
$6.27B
| – | – |
-12,000
| Closed | -$357K |
|
177
Tyra Biosciences
TYRA
$1.48B
| – | – |
-3,580,818
| Closed | -$137M |
|
178
UroGen Pharma
URGN
$2.19B
| – | – |
-11,000
| Closed | -$198K |
|
179
Visa
V
$707B
| – | – |
-840,710
| Closed | -$254M |
|
180
Veracyte
VCYT
$3.59B
| – | – |
-7,000
| Closed | -$225K |
|
181
Vir Biotechnology
VIR
$1.94B
| – | – |
-22,000
| Closed | -$197K |
|
182
Vertiv
VRT
$103B
| – | – |
-19,000
| Closed | -$4.76M |
|
183
Western Alliance Bancorporation
WAL
$8.84B
| – | – |
-73,000
| Closed | -$5.17M |
|
184
GeneDx Holdings
WGS
$2.61B
| – | – |
-5,000
| Closed | -$321K |
|
|
ALMS
185
Alumis Inc
ALMS
$1.47B
| – | – |
-11,000
| Closed | -$242K |
|
|
IRD
186
Opus Genetics
IRD
$383M
| – | – |
-1,000,000
| Closed | -$4.55M |
|
|
ONC
187
BeOne Medicines Ltd
ONC
$41B
| – | – |
-1,100
| Closed | -$327K |
|
|
TVRD
188
Tvardi Therapeutics
TVRD
$24.7M
| – | – |
-21,438
| Closed | -$68.2K |
|
|
BITW
189
Bitwise 10 Crypto Index ETF
BITW
$795M
| – | – |
-603,000
| Closed | -$26.9M |
|
|
RNA
190
Atrium Therapeutics
RNA
$250M
| – | – |
-349,360
| Closed | -$4.67M |
|
Similar funds
BG
IC
OSAM
SA
BPA
CHP
PAG
ETC
Farallon Capital Management's Q2 2026 Portfolio in Review
As of Q2 2026, Farallon Capital Management held 194 positions worth $21.7B, up 14% from $19.1B the previous quarter. Its ten largest holdings account for 62% of the portfolio.
Farallon Capital Management withdrew a net $3.46B in Q2 2026, closing 105 positions and reducing 23 holdings. Its most notable exit was Charles Schwab, an estimated $372M position sold in full.
By sector, the portfolio is most concentrated in Healthcare at 55% of assets, up from 47% a quarter earlier, followed by Miscellaneous and Communication Services.
Against the trend, Farallon Capital Management opened a new position in Parabilis Medicines Inc worth $64.8M.
- Farallon Capital Management's largest Q2 2026 buy was Parabilis Medicines Inc: 2,368,200 shares worth $64.8M.
- Farallon Capital Management added most to Boston Scientific in Q2 2026, an estimated $166M increase.
- Farallon Capital Management's biggest Q2 2026 reduction was Microsoft, cutting an estimated $498M.
- Farallon Capital Management fully exited Charles Schwab in Q2 2026, selling an estimated $372M.
- Farallon Capital Management's ten largest holdings make up 62% of its $21.7B portfolio in Q2 2026.
- Farallon Capital Management opened 19 new positions and closed 105 in Q2 2026.
- Farallon Capital Management's portfolio value rose 14% quarter-over-quarter to $21.7B.
Based on Farallon Capital Management's 13F filing for Q2 2026, filed 14 Aug 2026.